Sino BiopharmaceuticalSBMFF -4.96%62 Pretax Margin % is 6.85% as of Dec. 2025, which is 70% below its 10-year median of 22.65. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Sino Biopharmaceutical ranks better than 87.18% on this metric.
The historical rank and industry rank for Sino Biopharmaceutical's Pretax Margin % or its related term are showing as below:
SBMFF'
s Pretax Margin % Range Over the Past 10 Years
Min: 18.28 Med: 22.65 Max: 69.14
Current: 21.74
SBMFF's Pretax Margin % is ranked better than 87.18% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs SBMFF: 21.74
Sino Biopharmaceutical (OTCPK:SBMFF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sino Biopharmaceutical Pretax Margin % Related Terms
Sino Biopharmaceutical Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a Pretax Margin % of 6.85% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sino Biopharmaceutical and its competitors. This is 70% below median its historical median of 22.65. Over the past decade, Sino Biopharmaceutical's Pretax Margin % has ranged from 18.28 to 69.14. According to the industry distribution chart, Sino Biopharmaceutical ranks #121 out of 944 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Sino Biopharmaceutical's Pretax Margin % too high?
Sino Biopharmaceutical's current Pretax Margin % of 6.85% is 70% below median its 10-year median of 22.65. Over the past 10 years, this metric has ranged from a low of 18.28 to a high of 69.14. Based on the distribution chart, Sino Biopharmaceutical ranks #121 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #121 out of 944 companies for Pretax Margin %. This places Sino Biopharmaceutical in the top 13% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own Pretax Margin % has ranged from 18.28 to 69.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Pretax Margin % is 6.85%, which is 70% below median its own 10-year median of 22.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.67, compared to a current price of $0.60 — trading 10.2% below its estimated fair value. The current Pretax Margin % is 6.85%, which is 70% below median its 10-year median of 22.65. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Pretax Margin % is 6.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 10.2% below its estimated GF Value™ of $0.67.
GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.
Key valuation signals for SBMFF:
Pretax Margin %: 6.85% (70% below median its 10-year median of 22.65)
GF Value™: $0.67 vs. price of $0.60 (10.2% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
